Scrutexity
Device Claim Review · AuditGPT

Before your clinic sells a device, know what you can safely claim about it.

AuditGPT reviews device pages, supplier claims, FDA-status language, evidence gaps, and AI answer risk for red light, hair-growth, PEMF, body-contouring, EMS, RF microneedling, and aesthetic-device offers.

Not legal, regulatory, FDA, import, customs, or clinical advice. Claim language and evidence review only.

Why device claims are risky

Cleared for a specific use — marketed for everything.

FDA 510(k) clearance applies to a specific device, for a specific intended use, in a specific patient population. When clinics and suppliers market those same devices for broader uses — "tightens all skin," "eliminates fat permanently," "reverses aging" — the claim has moved past what the clearance supports.

AI search engines then crawl those pages and repeat the overclaim in AI-generated answers to patient questions — creating a second layer of distortion that the clinic cannot directly edit.

Cleared ≠ approved ≠ safe for all

FDA "clearance" through 510(k) means a device is substantially equivalent to a predicate. It does not mean FDA approved the treatment outcome, the patient population, or every marketed application.

"Non-invasive" is often inaccurate

RF microneedling uses needles that penetrate skin. Laser treatments create thermal injury. "Non-invasive" applied to these procedures can be directly inaccurate.

EMS weight-loss is a red-zone category

Girth reduction, fat elimination, or weight-loss outcome claims applied to EMS devices frequently outrun the cleared indication and available evidence.

Exosome products have no FDA approval

FDA public safety notices state there are no FDA-approved exosome products for any use. Marketing them as "FDA-reviewed regenerative therapy" is not supportable.

Category risk matrix

Not all device categories carry the same claim risk.

This matrix reflects the current claim-review risk profile, not FDA clearance status. A green-tier device can still have individual claims that require rewrite.

Lower-risk starting point

Hair-growth laser caps and helmets

FDA 510(k)-cleared devices exist in this category for specific androgenic alopecia indications. Claims must match cleared indication and population exactly.

Selected red-light therapy products

Where specific evidence exists for a specific use and device, careful claim framing is possible. Evidence must be product-specific, not category-level.

Requires careful claim framing

PEMF mats

Some cleared indications exist. Claims must be restricted to cleared uses; wellness and anti-aging positioning requires careful framing.

Body-contouring-adjacent devices

Fat-reduction claims must cite specific cleared device, specific indication, and avoid weight-loss or permanence framing.

General wellness red-light positioning

Broad "wellness" framing is defensible only when claims are evidence-backed, device-specific, and do not imply treatment of disease.

RF microneedling

FDA safety notices have highlighted serious adverse events. "No downtime," "painless," and "safe for everyone" language requires specific patient-selection and risk disclosures.

High-risk — review required before any public claim

EMS weight-loss or girth-reduction claims

Claims implying weight loss, fat elimination, or permanent girth reduction from EMS devices are a red-zone category. These claims lack adequate substantiation for most marketed outcomes and are a documented FTC/FDA concern.

Exosome or stem-cell products marketed as approved therapies

FDA public safety notices state there are no FDA-approved exosome products for any use. Marketing these as approved, clinical, or disease-treating is directly contradicted by public FDA guidance.

Any device claiming to cure, treat, reverse, or prevent disease

Drug or disease claims on devices require FDA approval or clearance for that specific indication. "Reverses aging," "cures acne," "treats depression" applied to devices without FDA clearance creates significant regulatory exposure.

Compounded drug + device combination claims

If a device claim is bundled with a compounded drug claim, both layers of risk compound. Treat each claim surface separately.

What gets reviewed

Seven claim surfaces reviewed on every device page.

Supplier claim language

Public claims made by the supplier or manufacturer, including catalogs, websites, and sales materials.

FDA-status language check

Whether 510(k) clearance numbers, cleared indications, exemptions, or registration data are accurately reflected in marketing language.

Cleared indication vs. marketed use

Whether the specific use being marketed matches the specific use the device was cleared for — these often diverge.

Before/after gallery claims

Result implication language, typicality disclosure, and outcome framing in device before/after galleries.

Safety and downtime claims

"No downtime," "painless," "non-invasive," and "safe for all skin types" language reviewed against device labeling and adverse-event disclosures.

AI answer distortion

Whether AI search engines repeat inaccurate device claims or FDA-status language from your public pages.

Supplier diligence materials

Where provided: QMS documentation, test reports, 510(k) numbers, labeling files, and country-of-origin marking.

Device Evidence Pack

A structured record of what the device can and cannot claim.

The Device Evidence Pack documents the claim-review process for a specific device — what the supplier claims, what FDA-status language is accurate, what evidence exists, and what clinic-safe marketing copy looks like. Not a regulatory approval. A documented evidence record.

Device Evidence Pack — fields

Device category
Hair-growth laser cap — Class II device
Intended use
Treatment of androgenic alopecia in adult patients, as cleared
Supplier claims reviewed
6 claims from supplier catalog and website
FDA-status language check
510(k) number K213456 reviewed; indication matches cleared use
510(k) / exemption notes
Cleared for home use in LLLT hair-growth indication; off-label scalp conditions not covered
Evidence summary
3 peer-reviewed studies cited by supplier; cohort sizes and endpoints reviewed
Known claim boundaries
Cannot claim hair regrowth "for all patients"; cannot claim treatment of alopecia areata
Red/yellow/green claim list
2 green, 3 yellow (qualify with indication), 1 red (remove)
Clinic-safe marketing copy
Safer rewrite pack delivered per claim
Supplier diligence checklist
Completed; 3 items pending (QMS docs, labeling file, U.S. agent confirmation)

Supplier Diligence Checklist

Document what you collected from the supplier before you committed.

This checklist is a documentation framework, not a supplier approval or regulatory certification. Completing it means you asked the right questions — not that the answers were independently verified.

Supplier Diligence Checklist

16 fields across 4 sections. Documentation framework, not supplier approval.

This checklist is a documentation framework, not a supplier approval or regulatory certification. Completing it means you asked the right questions — not that the answers were independently verified. Consult qualified legal, regulatory, and customs professionals before committing to any supplier or import.

This checklist is a diligence documentation aid. It does not constitute approval, certification, or regulatory clearance of any supplier, device, or claim.

Claim Cleanup Record handoff

Device Evidence Pack surfaced risky language. The Claim Cleanup Record fixes it.

A structured record showing what device claims were changed, why they were changed, what support now backs each claim, and which claims still require caution. $1,997 one-time.

Questions

What to know before submitting a device page.

Claim-reviewed device marketing. Before launch.

AuditGPT does not provide legal, medical, regulatory, FDA, import, customs, or clinical advice. It does not certify devices, suppliers, claims, imports, or compliance. It reviews public-facing claims, visible evidence, supplier-provided materials, and FDA-status language to identify proof gaps and safer marketing options.